Prognostic significance of p53, mTOR, c-Met, IGF-1R, and HSP70 overexpression after the resection of hepatocellular carcinoma

Gut and Liver

Volumn 8, Issue 1, 2014, Pages 79-87

  Kang, Gu Hyum ^a   Lee, Byung Seok ^a   Lee, Eaum Seok ^a   Kim, Seok Hyun ^a   Lee, Heon Young ^a   Kang, Dae Young ^a  

^a Chungnam National University   (South Korea)

Author keywords

C Met; Carcinoma hepatocellular; MTOR; P53; Receptor IGF type 1

Indexed keywords

BIOLOGICAL MARKER; HEAT SHOCK PROTEIN 70; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P53; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; OVERALL SURVIVAL; PORTAL VEIN; RETROSPECTIVE STUDY; SURVIVAL RATE; YOUNG ADULT;

C-MET; CARCINOMA, HEPATOCELLULAR; MTOR; P53; RECEPTOR, IGF TYPE 1;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, IGF TYPE 1; RETROSPECTIVE STUDIES; RISK FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84893148394     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2014.8.1.79     Document Type: Article

References (28)

1. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-687.
2. Tabor E. Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J Med Virol 1994;42:357-365.
3. Rogler CE, Chisari FV. Cellular and molecular mechanisms of hepatocarcinogenesis. Semin Liver Dis 1992;12:265-278.
4. Sung CO, Yoo BC, Koh KC, Cho JW, Park CK. Prognostic significance of p53 overexpression after hepatic resection of hepatocellular carcinoma. Korean J Gastroenterol 2005;45:425-430.
5. Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 2007;72 Suppl 1:30-44.
6. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-1327.
7. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462-503.
8. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 2001;81:1331-1338.
9. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878.
10. Osada S, Saji S, Kuno T. Clinical significance of combination study of apoptotic factors and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinoma. J Surg Oncol 2004;85:48-54.
11. Fujimoto Y, Hampton LL, Wirth PJ, Wang NJ, Xie JP, Thorgeirsson SS. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res 1994;54:281-285.
12. Song TJ, Fong Y, Cho SJ, et al. Comparison of hepatocellular carcinoma in American and Asian patients by tissue array analysis. J Surg Oncol 2012;106:84-88.
13. Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC. TP53 and liver carcinogenesis. Hum Mutat 2003;21:201-216.
14. Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000;10:185-200.
15. Ng IO, Lai EC, Chan AS, So MK. Overexpression of p53 in hepatocellular carcinomas: a clinicopathological and prognostic correlation. J Gastroenterol Hepatol 1995;10:250-255.
16. Jeng KS, Sheen IS, Chen BF, Wu JY. Is the p53 gene mutation of prognostic value in hepatocellular carcinoma after resection? Arch Surg 2000;135:1329-1333.
17. Nishida N, Fukuda Y, Kokuryu H, et al. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res 1993;53:368-372.
18. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology 2006;43(2 Suppl 1):S45-S53.
19. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-516.
20. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-348.
21. Schmitz KJ, Wohlschlaeger J, Lang H, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008;48:83-90.
22. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-518.
23. Scharf JG, Braulke T. The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 2003;35:685-693.
24. Didelot C, Schmitt E, Brunet M, Maingret L, Parcellier A, Garrido C. Heat shock proteins: endogenous modulators of apoptotic cell death. Handb Exp Pharmacol 2006;(172):171-198.
25. Chuma M, Sakamoto M, Yamazaki K, et al. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 2003;37:198-207.
26. Haratake J, Takeda S, Kasai T, Nakano S, Tokui N. Predictable factors for estimating prognosis of patients after resection of hepatocellular carcinoma. Cancer 1993;72:1178-1183.
27. Lauwers GY, Terris B, Balis UJ, et al. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol 2002;26:25-34.
28. Lai CL, Wu PC, Lam KC, Todd D. Histologic prognostic indicators in hepatocellular carcinoma. Cancer 1979;44:1677-1683.